You are here

Predicting and reducing hepatitis C reinfection following treatment

Description 
The availability of new direct-acting antiviral (DAA) treatment for hepatitis C has led to global targets to eliminate the public health impact of hepatitis C through treatment delivery, in conjunction with harm reduction services that minimise risk-taking behaviour. A key concern for individuals, population health and health economics is whether hepatitis C reinfection will occurs at higher rates after DAA treatment. Changes in risk-taking behaviour may lead to reinfection and negate successful hepatitis C treatment. This project aims to understand hepatitis C re-infection following treatment among key populations at-risk of hepatitis C, namely people who inject drugs, prisoners and gay and bisexual men. It will use behaviour data collected within existing projects - the Hepatitis C Treatment and Prevention Study and the Enhancing Care and Treatment in HIV/HCV coinfection (co-EC) Study. There is option of a mixed methods project to include In depth interviews of participants who have become reinfected post-treatment. The outcomes will be used to better design clinical services and health promotion for people at the time they are undertaking HCV treatment.
Essential criteria: 
Minimum entry requirements can be found here: https://www.monash.edu/admissions/entry-requirements/minimum
Keywords 
hepatitis, HIV, reinfection, people who inject drugs, gay and bisexual men
Available options 
PhD/Doctorate
Masters by research
Honours
BMedSc(Hons)
Time commitment 
Full-time
Part-time
Top-up scholarship funding available 
No
Physical location 
Alfred Research Alliance
Co-supervisors 
Prof 
Margaret Hellard

Want to apply for this project? Submit an Expression of Interest by clicking on Contact the researcher.